Business Description

Description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
Name Current Vs Industry Vs History
Cash-To-Debt
1166.24
Equity-to-Asset
-0.03
Debt-to-Equity
-0.02
Interest Coverage
No Debt
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-0.58
Distress
Grey
Safe
Beneish M-Score
2703.16
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
-0.6
3-Year EPS without NRI Growth Rate
11.8
3-Year Book Growth Rate
-20.6
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
3.15
Quick Ratio
3.15
Cash Ratio
3.02
Days Sales Outstanding
56.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-22.4
Shareholder Yield %
-4.46

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin %
-548.07
Net Margin %
-219.94
EBITDA Margin %
-548.07
FCF Margin %
144.92
OCF Margin %
145.15
ROE %
-259.37
ROA %
-27.54
ROIC %
-91.85
3-Year ROIIC %
19.12
ROC (Joel Greenblatt) %
-35343.48
ROCE %
-88.23
Moat Score
3
Tariff Resilience Score
7

Financials

SBMJF's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:SBMJF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Dimerix Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 4.857
EPS (TTM) ($) -0.018
Beta 13.7197
3-Year Sharpe Ratio 0.58
3-Year Sortino Ratio 640.97
Volatility % -
14-Day RSI -
14-Day ATR ($) -
20-Day SMA ($) 0.35
12-1 Month Momentum % -
52-Week Range ($) 0.35 - 0.35
Shares Outstanding (Mil) 600.4

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Dimerix Ltd Filings

Filing Date Document Date Form
No Filing Data

Dimerix Ltd Stock Events

Financials Calendars
Event Date Price ($)
0.05:1 Stock Split 2017-10-23 0.00 (+0.00%)
0.071429:1 Stock Split 2012-10-04 --
Show
Entries

Dimerix Ltd Frequently Asked Questions

What is Dimerix Ltd(SBMJF)'s stock price today?
The current price of SBMJF is $0.35. The 52 week high of SBMJF is $0.35 and 52 week low is $0.35.
When is next earnings date of Dimerix Ltd(SBMJF)?
The next earnings date of Dimerix Ltd(SBMJF) is .
Does Dimerix Ltd(SBMJF) pay dividends? If so, how much?
Dimerix Ltd(SBMJF) does not pay dividend.

Guru Commentaries on OTCPK:SBMJF

No articles.

Articles on Dimerix Ltd

No articles.

Headlines

See More
  • 1
No news.
  • 1